Compare AbCellera Biologics Inc (ABCL) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Kimberly Clark Corp — how do they compare? AbCellera Biologics Inc trades at $9.26 (market cap $2.99B), while Kimberly Clark Corp trades at $108.02 (market cap $36.11B). The key difference: Kimberly Clark Corp is far larger — about 12.1× AbCellera Biologics Inc's market cap, and Kimberly Clark Corp pays a 4.72% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | KMB | |
|---|---|---|
Market Cap | $2.99B | $36.11B |
Sector | Health | Consumer Staples |
52-Week High | $9.76 | $134.81 |
52-Week Low | $2.78 | $93.05 |
Enterprise Value | $2.58B | $41.67B |
Dividend Yield | — | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
